文献速递血管炎其他结缔组织病

早期启用美泊利珠单抗与EGPA器官损害负担降低相关:多中心队列研究

Early mepolizumab initiation during remission induction is associated with lower organ damage burden in EGPA: a multicentre cohort study.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

早期组1年临床缓解率更高(69% vs 27%,P=0.006),2年缓解率更高(10/10 vs 13/45,P<0.001),且纵向VDI值更低(β=-0.36,95%CI -0.70至-0.03,P=0.032)。

要点

  • 诱导缓解3个月内启用美泊利珠单抗与1年及2年更高缓解率相关。
  • 早期启用与纵向VDI值更低相关,提示器官损害负担更轻。
  • 早期组2年糖皮质激素停用比例更高(40% vs 9%,P=0.029)。

核心结论

  • 在EGPA患者中,诱导缓解期间早期启用美泊利珠单抗与更高的缓解率、更低的糖皮质激素暴露及更低的器官损害负担相关。

主要发现

  • 1年临床缓解率早期组为69%、常规组为27%(P=0.006)。
  • 2年缓解在可评估患者中早期组为10/10(100%)、常规组为13/45(29%)(P<0.001)。
  • 2年糖皮质激素停用在可评估患者中早期组为4/10(40%)、常规组为4/45(9%)(P=0.029)。
  • 早期启用美泊利珠单抗与纵向VDI值更低相关(β=-0.36,95%CI -0.70至-0.03;P=0.032)。
  • 两组的BVAS均显著下降。

关键数值与推荐

  • 早期美泊利珠单抗组定义为诱导缓解3个月内启用美泊利珠单抗。
  • 主要终点为1年临床缓解,定义为BVAS=0且泼尼松龙≤4 mg/day。

临床怎么用

  • 对于EGPA患者,可考虑在诱导缓解早期启用美泊利珠单抗,以期提高缓解率并减轻器官损害负担。

局限性

  • 本研究为回顾性队列研究,早期组样本量较小(16例),可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective of this study was to evaluate whether early mepolizumab initiation during remission induction is associated with favourable clinical outcomes and lower organ damage burden in patients with eosinophilic granulomatosis with polyangiitis (EGPA). METHODS: This retrospective multicentre cohort study used data from the Kyushu Vasculitis Cohort Study. Patients with EGPA were classified into an early mepolizumab group, in which mepolizumab was initiated within 3 months of remission induction, and a conventional group. The primary end point was clinical remission at 1 year, defined as BVAS = 0 with prednisolone ≤4 mg/day. Secondary end points included remission at 6 months and 2 years, glucocorticoid exposure, relapse, mortality, and organ damage as assessed by the Vasculitis Damage Index (VDI). Longitudinal VDI values from 6 months to 2 years were analysed using a linear mixed-effects model. RESULTS: Sixty-four patients were included (early mepolizumab, n = 16; conventional, n = 48). Clinical remission at 1 year was achieved more frequently in the early mepolizumab group than in the conventional group (69% vs 27%; P = 0.006). At 2 years, remission was achieved in 10/10 (100%) vs 13/45 (29%) evaluable patients (P < 0.001), and glucocorticoid discontinuation was achieved in 4/10 (40%) vs 4/45 (9%) of those patients (P = 0.029). BVAS decreased markedly in both groups. Early mepolizumab initiation was associated with lower longitudinal VDI values (β = -0.36, 95% CI -0.70 to -0.03; P = 0.032). CONCLUSION: Early mepolizumab initiation was associated with higher remission rates, lower glucocorticoid exposure and lower organ damage burden during the first 2 years in EGPA.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Maruyama A, Ono N, Kai T, et al. Early mepolizumab initiation during remission induction is associated with lower organ damage burden in EGPA: a multicentre cohort study. Rheumatology (Oxford). 2026. PMID: 42765531. doi:10.1093/rheumatology/keag523

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。